Advanced MRI method validates early diagnosis and treatment tracking for Multiple System Atrophy (MSA).

Alterity Therapeutics announced a peer-reviewed study showing that quantitative susceptibility mapping (QSM) MRI can detect disease-specific iron buildup in Multiple System Atrophy (MSA) patients, distinguish MSA from Parkinson's disease, and correlate with disease severity. This imaging biomarker supports earlier diagnosis and monitoring of iron-modulating therapies, including Alterity's drug candidate ATH434, which is advancing to Phase 3 trials. The study used data from the bioMUSE Natural History Study and confirmed that iron accumulation progresses with clinical decline, reinforcing QSM's role in MSA treatment development.